Adoptive Cell Therapy – Clinical Trials Overview and Analysis
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report provides an overview of Adoptive Cell Therapy clinical trials captured in the GlobalData Pharma Intelligence Center until May 1, 2024. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
As the number of Adoptive Cell Therapy clinical trials continues to increase, a deeper understanding of these trials, such as sponsor type, therapy areas, location, and phase, are reviewed.
Scope
1) A total of 42% of all adoptive cell therapy trials are ongoing. As most trials are ongoing, there may be an upcoming influx of novel adoptive cell therapies. These therapies are still new. It has only been seven years since the first CAR-T therapies were commercialized. This may also highlight the increased difficulty with advancing these therapies to completion.
2) CAR-T treatments account for 83% of all T cell immunotherapy trials and 55% all adoptive cell therapy trials.
3) APAC surpassed North America in 2016 for adoptive cell therapy trials and has maintained its dominance since then.
Key Highlights
1) A total of 42% of all adoptive cell therapy trials are ongoing. As most trials are ongoing, there may be an upcoming influx of novel adoptive cell therapies. These therapies are still new. It has only been seven years since the first CAR-T therapies were commercialized. This may also highlight the increased difficulty with advancing these therapies to completion. 2) CAR-T treatments account for 83% of all T cell immunotherapy trials and 55% all adoptive cell therapy trials. 3) APAC surpassed North America in 2016 for adoptive cell therapy trials and has maintained its dominance since then.
Reasons to Buy
This report Identifies key analysis and segments adoptive cell therapy trials by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and decentralized clinical trial use.
Examines the cause of the increase of psychedelic clinical trials.
Gives reasons for certain trends seen in psychedelic trials.
Breaks down trials by sponsor type and top sponsors.
Looks at the virtual components used for psychedelic trials.
Describes the leading drugs used in psychdelic trials.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Cell Therapy reports